Jade Biosciences, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Jade Biosciences, Inc. (JBIO) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 12.29 million shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-03-30
- Jade Biosciences, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 24.63M shares, a 10033.84% increase year-over-year.
- Jade Biosciences, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 23.89M shares, a 9733.23% increase year-over-year.
- Jade Biosciences, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 243.08K shares, a 0.67% increase year-over-year.
- Jade Biosciences, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 243.08K shares.
- Jade Biosciences, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 12.29M shares, a 4975.15% increase from fiscal 2020.
- Jade Biosciences, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 242.23K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | 24.63M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 24.26M shares derived: average of 2 quarters · filed 2022-03-30 | 16.25M shares derived: average of 3 quarters · filed 2022-03-30 | 12.29M shares 10-K · filed 2022-03-30 |
| 2021-09-30 | 23.89M shares 10-Q · filed 2021-11-15 | 12.06M shares derived: average of 2 quarters · filed 2021-11-15 | 8.18M shares 10-Q · filed 2021-11-15 | |
| 2021-06-30 | 243.08K shares 10-Q · filed 2021-08-16 | 243.08K shares 10-Q · filed 2021-08-16 | ||
| 2020-12-31 | 243.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 242.99K shares derived: average of 2 quarters · filed 2022-03-30 | 242.48K shares derived: average of 3 quarters · filed 2022-03-30 | 242.23K shares 10-K · filed 2022-03-30 |
| 2020-09-30 | 242.90K shares 10-Q · filed 2021-11-15 | 242.18K shares derived: average of 2 quarters · filed 2021-11-15 | 241.95K shares 10-Q · filed 2021-11-15 | |
| 2020-06-30 | 241.47K shares 10-Q · filed 2021-08-16 | 241.47K shares 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |